Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04638751 · ClinicalTrials.gov registry record
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
A clinical trial of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Persephone Biosciences.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 10
- Study locations
NCT04638751: Recruiting study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Persephone Biosciences.
NCT04638751 is a study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by Persephone Biosciences. The registered enrollment target is 5,000 participants, above the 641-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (680% higher). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04638751, a study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Persephone Biosciences.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 10
- Study locations
Study Summary
ARGONAUT is a longitudinal, prospective, observational study that will enroll up to 5,000 advanced-stage cancer patients of diverse racial backgrounds to collect data used to develop precision microbiome medicines and for the identification of clinically actionable cancer-specific biomarkers to guide therapeutic decisions. Four types of solid tumor cancers will be profiled including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), colorectal cancer (CRC) and pancreatic cancer. Healthy control subjects without a cancer diagnosis will also be studied, comprised of individuals at high risk for CRC and healthy individuals at low risk for CRC. Risk assessment will be based on family history or past neoplastic findings during CRC screening. Data collected from this study will be used to develop the most effective new therapies, via microbiome optimization, all to the benefit of patients and the physicians treating them. Stool and blood samples will be collected longitudinally and analyzed to determine the impact of gut microbiome composition and function on the immune system and efficacy of the treatment. Currently enrolling the CRC, high risk, and low risk cohorts. Subjects who meet the entry criteria will provide up to 5 samples each of blood and stool over a 2-year period. Approximately 10%-20% of the subjects will provide colon tissue samples, either from research biopsies during Standard of Care (SOC) screening colonoscopy or retained surgical tissue from colectomy. Electronic health records will be obtained at various times for up to 8 years, to collect tumor imaging results and any other updated medical data, with no additional samples collected. In select cases, stool and blood samples will be collected beyond 2 years.
Conditions Studied
Interventions
- PROCEDURE Colonoscopy
- DRUG Chemotherapy
- DRUG Immunotherapy
- PROCEDURE CRC surgical resection
Study Locations (10)
California
- Knowledge Research Center - Orange
- SDG Clinical Research, Inc - San Diego
- Persephone Biosciences, Inc. - San Diego
Louisiana
- Baton Rouge General Medical Center - Baton Rouge
- University Medical Center New Orleans - New Orleans
Texas
- Southwest Family Medicine Associates - Dallas
- Biopharma Informatic - Houston
Florida
- L&A Morales Healthcare, Inc - Miami
New York
- Mid-Hudson Medical Research - New Windsor
Ohio
- Kroger Health, The Little Clinic - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2025-12-31 |
What NCT04638751 shows while recruiting
NCT04638751 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 641-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (680% higher).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Colonoscopy is the first listed.
NCT04638751 lists 10 locations in 6 states (California, Louisiana, Texas).
Frequently Asked Questions
What is clinical trial NCT04638751 about?
NCT04638751 is a clinical study titled "ARGONAUT: Stool and Blood Sample Bank for Cancer Patients". ARGONAUT is a longitudinal, prospective, observational study that will enroll up to 5,000 advanced-stage cancer patients of diverse racial backgrounds to collect data used to develop precision microbiome medicines and for the identification of clinically actionable cancer-specific biomarkers to guid...
What is the current status of trial NCT04638751?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2022-07-01. Estimated completion is 2025-12-31.
What conditions does trial NCT04638751 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer.
What interventions are being tested in trial NCT04638751?
The interventions under investigation include: Colonoscopy (PROCEDURE), Chemotherapy (DRUG), Immunotherapy (DRUG), CRC surgical resection (PROCEDURE).
Who is sponsoring clinical trial NCT04638751?
This trial is sponsored by Persephone Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04638751 being conducted?
This trial has 10 study locations across California, Florida, Louisiana, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04638751's enrollment target sits among peer trials
5,000 5th of 454 higher than 450 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI